Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post-vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been explicitly tested in this population due to their common exclusion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a history of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durability of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis.
- Karakizlis, H.
- Nahrgang, C.
- Strecker, K.
- Chen, J.
- Aly, M.
- Slanina, H.
- Schüttler, C. G.
- Esso, I.
- Wolter, M.
- Todorova, D.
- Jessen, S.
- Adamik, A.
- Ronco, C.
- Seeger, W.
- Weimer, R.
- Sester, M.
- Birk, H. W.
- Husain-Syed, F.
Keywords
- Cellular immune response
- Hemodialysis
- Immunoglobulins
- Peritoneal dialysis
- SARS-CoV-2
- T cells
